UCLA researchers identified EPAC2 as a potential Fragile X syndrome treatment target after improving behavioral and brain activity patterns in mice.
Carlos Portera-Cailliau, MD, PhD
Advertisement
Carlos Portera-Cailliau, MD, is a professor of neurology and neurobiology at UCLA and the UCLA Brain Research Institute.
Articles by Carlos Portera-Cailliau, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
FDA issues Warning Letter to SNOO Smart Sleeper maker over unauthorized sleep sacks, hospital bundle, and quality system failures
2
Chronicity, Symptom Variability, and Treatment Expectations in Pediatric Functional Constipation and IBS-C
3
Acoustic resonance therapy shows promise for pediatric chronic rhinitis
4
FDA approves generic baloxavir marboxil for flu treatment, prophylaxis
5